Seatrium (SGX:5E2) stock flat today as traders zero in on a late-February vessel deadline
15 January 2026
1 min read

Seatrium (SGX:5E2) stock flat today as traders zero in on a late-February vessel deadline

Singapore, Jan 15, 2026, 16:20 SGT — Regular session

  • Seatrium shares held steady at S$2.28 in afternoon trading, having fluctuated between S$2.26 and S$2.31 earlier.
  • Investors are zeroed in on a delivery milestone due late February, connected to a Maersk-linked wind vessel settlement
  • Next up: delivery updates, along with any follow-through in filings and cash-flow remarks

Seatrium Ltd shares held steady Thursday afternoon in Singapore, last seen at S$2.28 after fluctuating between S$2.26 and S$2.31. Trading volume reached roughly 11.1 million shares. (SG Investors)

The stock has leveled off following gains earlier in January, as investors await clarity on the planned handover of a wind turbine installation vessel—a WTIV—set for Feb. 28, along with the associated payment. A Jan. 14 note from Simply Wall St highlighted the vessel delivery and payment terms as key near-term factors influencing sentiment. (Simply Wall St)

Seatrium, an offshore, marine, and energy engineering firm based in Singapore, typically moves on project milestones and contract wins instead of consistent quarterly sales. The firm constructs and repairs rigs and specialized vessels and runs a ship chartering business, per its Reuters company profile. (Reuters)

The February deadline is key because the vessel was caught up in a contract dispute with Denmark’s Maersk. Seatrium announced in December that the dispute had been resolved and committed to delivering the WTIV by Feb. 28. Maersk is expected to pay the remaining $360 million of the $475 million contract, including $250 million through an interest-bearing credit facility lasting up to 10 years. (Reuters)

Operational milestones elsewhere are lending support to the stock this month. On Jan. 2, Seatrium announced via MarketScreener that Petrobras 78 (P-78) had reached “first oil” — the moment a project begins producing hydrocarbons — from a floating production, storage and offloading unit (FPSO) at Brazil’s Búzios field. (MarketScreener)

The company is pushing further into grid and offshore wind infrastructure. In December, GE Vernova announced that its consortium with Seatrium secured a contract from Dutch-German grid operator TenneT for BalWin5. This project involves a 2.2-gigawatt high-voltage direct current (HVDC) link designed to channel North Sea wind power into Germany’s grid. (GE Vernova)

The Maersk-linked vessel still stands as the main near-term swing factor. Under the settlement, Seatrium faces repayment risk on the credit portion, which is expected to come from cash flow generated by the vessel. Seatrium holds security interests, including a mortgage and priority rights, per gCaptain’s report on the deal. (gCaptain)

Traders are keeping an eye on whether the stock can stay within its recent range without any new headlines, especially as volumes remain high by local standards. Project-driven stocks often fall silent quickly, then jump on a single announcement.

Investors are zeroing in on the Feb. 28 delivery date for the WTIV, looking for confirmation on the handover and payment details. Any last-minute operational hiccups could still bump the timeline. (Marinelog)

Stock Market Today

  • BridgeBio Pharma Valuation After Attruby Uptake, BBP-418 Data, and Late-Stage Pipeline Momentum
    January 15, 2026, 6:33 AM EST. BridgeBio Pharma (BBIO) has drawn fresh attention after reporting more than 6,600 prescriptions for its ATTR-CM therapy Attruby, releasing interim Phase 3 data for BBP-418, and outlining a new TTR amyloid depleter program. Our latest analysis notes a 90-day share-price gain of 41.6% and a 3-year total shareholder return, with the stock near US$77.90. The fair value estimate stands around US$84.65, implying upside if late-stage programs convert to revenue and earnings. Analysts' consensus price target is US$63.81, with a range from US$41.00 to US$95.00. Risks include durability of Attruby, negative trial data, and regulatory delays. Valuation shows BridgeBio trading at a discount to our fair value, but a high P/S ratio (~42.4x vs 26.8x fair). A premium valuation hinges on execution and margin expansion.
UOL stock rises after S$1.5 billion Hougang Central land win — what investors watch next
Previous Story

UOL stock rises after S$1.5 billion Hougang Central land win — what investors watch next

BP stock slides in London as $5 billion write-down warning puts buyback in focus
Next Story

BP stock slides in London as $5 billion write-down warning puts buyback in focus

Go toTop